1-11 of 11
Michael Pollak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer

Cristiano Ferrario, John Mackey, Karen A. Gelmon, Nathalie Levasseur, Poul H. Sorensen, Htoo Zarni Oo, Gian L. Negri, Veronica W.L. Tse, Sandra E. Spencer, Grace Cheng, Gregg B. Morin, Sonia del Rincon, Tiziana Cotechini, Christophe Gonçalves, Charles C.T. Hindmarch, Wilson H. Miller, Jr, Mehdi Amiri, Tayebeh Basiri, Victor Villareal-Corpuz, Sam Sperry, Kevin Gregorczyk, Gonzalo Spera, Nahum Sonenberg, Michael Pollak
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (3): 491–502.
https://doi.org/10.1158/1078-0432.CCR-24-0841
Published: 03 February 2025
View article titled, Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
Open the PDF for Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression

Yirui Gui, Adriana Aguilar-Mahecha, Urszula Krzemien, Abdel Hosein, Marguerite Buchanan, Josiane Lafleur, Michael Pollak, Cristiano Ferrario, Mark Basik
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (23): 7229–7242.
https://doi.org/10.1158/1078-0432.CCR-19-1268
Published: 02 December 2019
View article titled, Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Open the PDF for Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression in another window
Includes: Supplementary data
Journal Articles

Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer

Neil M. Iyengar, Xi Kathy Zhou, Ayca Gucalp, Patrick G. Morris, Louise R. Howe, Dilip D. Giri, Monica Morrow, Hanhan Wang, Michael Pollak, Lee W. Jones, Clifford A. Hudis, Andrew J. Dannenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (9): 2283–2289.
https://doi.org/10.1158/1078-0432.CCR-15-2239
Published: 01 May 2016
View article titled, Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer
Open the PDF for Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer

Kim N. Chi, Martin E. Gleave, Ladan Fazli, S. Larry Goldenberg, Alan So, Christian Kollmannsberger, Nevin Murray, Anna Tinker, Michael Pollak
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3407–3413.
https://doi.org/10.1158/1078-0432.CCR-12-0482
Published: 14 June 2012
View article titled, A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer
Open the PDF for A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer in another window
Journal Articles

Metformin and Pancreatic Cancer: A Clue Requiring Investigation

Michael Pollak
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10): 2723–2725.
https://doi.org/10.1158/1078-0432.CCR-12-0694
Published: 14 May 2012
View article titled, Metformin and Pancreatic Cancer: A Clue Requiring Investigation
Open the PDF for Metformin and Pancreatic Cancer: A Clue Requiring Investigation in another window
Includes: Supplementary data
Journal Articles

The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology

Michael Pollak
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (1): 40–50.
https://doi.org/10.1158/1078-0432.CCR-11-0998
Published: 02 January 2012
View article titled, The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology
Open the PDF for The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology in another window
Journal Articles

Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

Fred Saad, Sebastien Hotte, Scott North, Bernie Eigl, Kim Chi, Piotr Czaykowski, Lori Wood, Michael Pollak, Scott Berry, Jean-Baptiste Lattouf, Som D. Mukherjee, Martin Gleave, Eric Winquist
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5765–5773.
https://doi.org/10.1158/1078-0432.CCR-11-0859
Published: 01 September 2011
View article titled, Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
Open the PDF for Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c in another window
Journal Articles

Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741

Charles S. Fuchs, Richard M. Goldberg, Daniel J. Sargent, Jeffrey A. Meyerhardt, Brian M. Wolpin, Erin M. Green, Henry C. Pitot, Michael Pollak
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8263–8269.
https://doi.org/10.1158/1078-0432.CCR-08-0480
Published: 15 December 2008
View article titled, Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741
Open the PDF for Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741 in another window
Journal Articles

Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer

Alan I. So, Randy J. Levitt, Bernhard Eigl, Ladan Fazli, Motosugu Muramaki, Sam Leung, Maggie C.U. Cheang, Torsten O. Nielsen, Martin Gleave, Michael Pollak
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 6944–6954.
https://doi.org/10.1158/1078-0432.CCR-08-0408
Published: 03 November 2008
View article titled, Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer
Open the PDF for Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer in another window
Journal Articles

The Type 1 Insulin-Like Growth Factor Receptor Pathway

Meenali M. Chitnis, John S.P. Yuen, Andrew S. Protheroe, Michael Pollak, Valentine M. Macaulay
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6364–6370.
https://doi.org/10.1158/1078-0432.CCR-07-4879
Published: 16 October 2008
View article titled, The Type 1 Insulin-Like Growth Factor Receptor Pathway
Open the PDF for The Type 1 Insulin-Like Growth Factor Receptor Pathway in another window
Journal Articles

Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel

Deborah Toppmeyer, Andrew D. Seidman, Michael Pollak, Christy Russell, Katherine Tkaczuk, Shailendra Verma, Beth Overmoyer, Varun Garg, Ene Ette, Matthew W. Harding, George D. Demetri
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (3): 670–678.
Published: 01 March 2002
View article titled, Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel
Open the PDF for Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel in another window